176 related articles for article (PubMed ID: 27344295)
1. Re: Nizar M. Tannir, Eric Jonasch, Laurence Albiges, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN):A Randomized Multicenter Phase 2 Trial. Eur Urol 2016;69:866-74.
Yang Z; Qi L; Chen M
Eur Urol; 2017 Jan; 71(1):e23-e24. PubMed ID: 27344295
[No Abstract] [Full Text] [Related]
2. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
[TBL] [Abstract][Full Text] [Related]
3. Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14.
Lei Y; Yildiz S; Chen M
Eur Urol; 2017 Sep; 72(3):e72-e73. PubMed ID: 28108150
[No Abstract] [Full Text] [Related]
4. Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405-14.
Hsieh JJ; Marker M; Chen D
Eur Urol; 2017 Sep; 72(3):e74-e75. PubMed ID: 28111113
[No Abstract] [Full Text] [Related]
5. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
[No Abstract] [Full Text] [Related]
6. Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6: Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?
de Joode K; van der Veldt AAM
Eur Urol; 2020 Mar; 77(3):e76-e77. PubMed ID: 31610901
[No Abstract] [Full Text] [Related]
7. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.
Msaouel P; Zurita AJ; Huang S; Jonasch E; Tannir NM
Oncotarget; 2017 Jun; 8(26):42149-42158. PubMed ID: 28178674
[TBL] [Abstract][Full Text] [Related]
8. Kidney cancer: Sunitinib versus everolimus for non-clear-cell renal cell carcinoma.
Kelsey R
Nat Rev Urol; 2016 Mar; 13(3):124. PubMed ID: 26832163
[No Abstract] [Full Text] [Related]
9. Comparing Everolimus to Sunitinib in Non-clear-cell Renal Cell Carcinoma.
Bex A; Ljungberg B
Eur Urol; 2016 May; 69(5):875-6. PubMed ID: 26626618
[No Abstract] [Full Text] [Related]
10. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
[No Abstract] [Full Text] [Related]
11. Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. In press. https://doi.org/10.1158/1078-0432.ccr-20-2063.
Rizzo A; Mollica V; Massari F
Eur Urol Oncol; 2020 Dec; 3(6):804-805. PubMed ID: 33121939
[No Abstract] [Full Text] [Related]
12. Re: Partial nephrectomy in the setting of metastatic renal cell carcinoma: K. N. Babaian, M. M. Merrill, S. Matin, P. Tamboli, N. M. Tannir, E. Jonasch, C. G. Wood and J. A. Karam J Urol 2014; 192: 36-42.
Giri V; Jha AK; Yadav SS
J Urol; 2015 Feb; 193(2):733; discussion 733-4. PubMed ID: 25445577
[No Abstract] [Full Text] [Related]
13. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
Voss MH; Chen D; Marker M; Hakimi AA; Lee CH; Hsieh JJ; Knox JJ; Voi M; Motzer RJ
Br J Cancer; 2016 Mar; 114(6):642-9. PubMed ID: 26908330
[TBL] [Abstract][Full Text] [Related]
14. Re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2023;83:3-5.
Tang Y; Hu X; Wu K; Shao Y; Li X
Eur Urol; 2023 Mar; 83(3):e73. PubMed ID: 36526493
[No Abstract] [Full Text] [Related]
15. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
Di Lorenzo G; Casciano R; Malangone E; Buonerba C; Sherman S; Willet J; Wang X; Liu Z; De Placido S
Expert Opin Pharmacother; 2011 Jul; 12(10):1491-7. PubMed ID: 21599551
[TBL] [Abstract][Full Text] [Related]
16. Reply to Yongbao Wei, Ruochen Zhang, and Le Lin's Letter to the Editor re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82:e88.
Ljungberg B; Bedke J; Capitanio U; Bex A
Eur Urol; 2022 Oct; 82(4):e111-e112. PubMed ID: 35773149
[No Abstract] [Full Text] [Related]
17. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
Paule B; Brion N
Anticancer Res; 2011 Oct; 31(10):3507-10. PubMed ID: 21965770
[TBL] [Abstract][Full Text] [Related]
18. Re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006.
Wei Y; Zhang R; Lin L
Eur Urol; 2022 Sep; 82(3):e88. PubMed ID: 35750581
[No Abstract] [Full Text] [Related]
19. RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis.
Yang L; Alyasova A; Ye D; Ridolfi A; Dezzani L; Motzer RJ
BMC Cancer; 2018 Feb; 18(1):195. PubMed ID: 29454306
[TBL] [Abstract][Full Text] [Related]
20. Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Serova M; Tijeras-Raballand A; Dos Santos C; Martinet M; Neuzillet C; Lopez A; Mitchell DC; Bryan BA; Gapihan G; Janin A; Bousquet G; Riveiro ME; Bieche I; Faivre S; Raymond E; de Gramont A
Oncotarget; 2016 Jun; 7(25):38467-86. PubMed ID: 27509260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]